MedTrace Logo

Insulin Degludec Titration Using Mobile Insulin Dosing System

NCT03091712 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2020-03-05

No results posted yet for this study

Summary

This is an open label randomized, controlled, parallel intervention study. Group 1 will receive usual care for insulin degludec titration using the STEP WISE degludec titration algorithm Group 2 will receive Glooko mobile insulin dosing system, using the STEP WISE degludec titration algorithm.An estimated n= 240 subjects with type 2 diabetes will be enrolled in order to obtain approximately 200 evaluable subjects who will complete the 16 week study.

Conditions

Interventions

DEVICE

Glooko Mobile Insulin Dosing System(MIDS)

Mobile Insulin Dosing System (MIDS) for all long acting insulin degludec titration management

Sponsors & Collaborators

  • Glooko

    lead INDUSTRY

Principal Investigators

  • Michael Greenfield, MD · Glooko

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-05
Primary Completion
2019-08-08
Completion
2019-09-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03091712 on ClinicalTrials.gov